Cargando…
Successful Treatment of Persistent Symptomatic Coronavirus Disease 19 Infection With Extended-Duration Nirmatrelvir-Ritonavir Among Outpatients With Hematologic Cancer
Persistent symptomatic coronavirus disease 2019 (COVID-19) is a distinct clinical entity among patients with hematologic cancer and/or profound immunosuppression. The optimal medical management is unknown. We describe 2 patients who had symptomatic COVID-19 for almost 6 months and were successfully...
Autores principales: | Liu, Catherine, Yoke, Leah H, Bhattacharyya, Pooja, Cassaday, Ryan D, Cheng, Guang-Shing, Escobar, Zahra Kassamali, Ghiuzeli, Cristina, McCulloch, Denise J, Pergam, Steven A, Roychoudhury, Pavitra, Tverdek, Frank, Schiffer, Joshua T, Ford, Emily S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296060/ https://www.ncbi.nlm.nih.gov/pubmed/37383248 http://dx.doi.org/10.1093/ofid/ofad306 |
Ejemplares similares
-
Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022) -
Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022) -
Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022) -
523. Efficacy and Safety of Nirmatrelvir/Ritonavir for COVID-19 in Adolescents
por: Lee, Kiriam Escobar, et al.
Publicado: (2023) -
Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models
por: Cox, Robert M., et al.
Publicado: (2023)